Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Empagliflozin's CV Benefit Impresses At EASD, But What Will FDA Say?

This article was originally published in The Pink Sheet Daily

Executive Summary

Boehringer/Lilly's Jardiance delivers impressive CV death benefit but no effect on myocardial infarction or stroke – prompting questions about relevance of MACE composite primary endpoint.


Related Content

Sanofi's Lixisenatide Gets Clean Bill Of Health On CV Safety, Heart Failure
FDA Warning On SGLT-2 Drugs Raises Specter Of Labeling Change
At Liraglutide Panel Review, A Call For CV Studies To Look Beyond MACE
Alogliptin, Saxagliptin Show Neutral CV Effects In Outcomes Studies


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts